AC102 Eliminates Tinnitus in Preclinical Study
Experimental Drug AC102 Significantly Reverses Tinnitus and Repairs Auditory Damage in Preclinical Study A groundbreaking preclinical study has shown that a single dose of the novel compound AC102 can nearly…
Sunshine Biopharma Launches NIOPEG® into $10B Biologics Market
Sunshine Biopharma Launches NIOPEG® Biosimilar in Canada, Targeting $10B Biologics Market Sunshine Biopharma Inc. (NASDAQ: SBFM), a pharmaceutical company focused on developing and commercializing life-saving medicines across oncology, antiviral therapies,…
Pneumagen Publishes Positive Phase II Data for Broad-Spectrum Antiviral Neumifil
Pneumagen Publishes Promising Phase II Results of Neumifil in Peer-Reviewed Journal, Demonstrating Potential as Broad-Spectrum Antiviral for Respiratory Infections Pneumagen, a clinical-stage biotechnology company focused on developing broad-spectrum antivirals, announced…
Abeona Sells Priority Review Voucher for $155 Million
Abeona Therapeutics Secures $155 Million from Sale of Priority Review Voucher, Strengthening Financial Position Ahead of ZEVASKYN Launch Abeona Therapeutics Inc. (Nasdaq: ABEO), a clinical-stage biopharmaceutical company focused on developing…
BriaCell Adds New Phase 3 Trial Sites, Including Yale and LA Cancer Network
BriaCell Expands Phase 3 Breast Cancer Trial to Major U.S. Centers, Targets Enrollment Completion by 2026 BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ; TSX: BCT), a clinical-stage biotechnology company pioneering…
Alume Biosciences Publishes First-in-Human Bevonescein Nerve Imaging Data in Nature Communications
Alume Biosciences Publishes First-in-Human Data on Bevonescein for Nerve Imaging in Nature Communications Alume Biosciences, a late-clinical stage biotechnology company focused on improving surgical safety through nerve-illuminating technologies, has announced…
JCR Pharmaceuticals Completes Enrollment in JR-141 Phase III Trial
JCR Pharmaceuticals Completes Enrollment in Global Phase III Trial for JR-141 Targeting Hunter Syndrome JCR Pharmaceuticals Co., Ltd. (TSE 4552; JCR) has announced the successful completion of participant enrollment for…
OXLUMO® Now Reimbursed in Canada for PH1 Treatment
OXLUMO® (Lumasiran) Secures National Reimbursement in Canada for Treatment of Primary Hyperoxaluria Type 1 Alnylam Canada ULC has announced that OXLUMO® (lumasiran), a first-in-class RNA interference (RNAi) therapeutic, is now…
FDA Grants Accelerated Approval to Lynozyfic for Relapsed Multiple Myeloma
Regeneron’s Lynozyfic™ Secures FDA Accelerated Approval for Heavily Pretreated Multiple Myeloma Patients Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval…
Givastomig Shows Promise in 1L Gastric Cancer: I-Mab at ESMO GI 2025
I-Mab Presents Positive Phase 1b Data for Givastomig in Combination with Nivolumab and Chemotherapy in 1L Gastric Cancer at ESMO GI 2025 I-Mab (NASDAQ: IMAB), a U.S.-based global biotechnology company…
Asahi Kasei Pharma Launches Global Phase III Trial of ART-123 for CIPN Prevention
Asahi Kasei Pharma Initiates Phase III Clinical Trial of ART-123 to Combat Chemotherapy-Induced Peripheral Neuropathy Asahi Kasei Pharma Corporation has officially commenced drug administration in a pivotal Phase III clinical…
WHO Launches Drive to Boost Health Taxes, Save Lives
WHO Unveils “3 by 35” Health Tax Initiative to Combat NCDs and Boost Public Revenue The World Health Organization (WHO) has launched a bold and far-reaching global campaign aimed at…